[go: up one dir, main page]

CL2016000379A1 - Composiciones y métodos terapéuticos para reducción acelerada de plagas - Google Patents

Composiciones y métodos terapéuticos para reducción acelerada de plagas

Info

Publication number
CL2016000379A1
CL2016000379A1 CL2016000379A CL2016000379A CL2016000379A1 CL 2016000379 A1 CL2016000379 A1 CL 2016000379A1 CL 2016000379 A CL2016000379 A CL 2016000379A CL 2016000379 A CL2016000379 A CL 2016000379A CL 2016000379 A1 CL2016000379 A1 CL 2016000379A1
Authority
CL
Chile
Prior art keywords
accelerated
compositions
therapeutic methods
pest reduction
pest
Prior art date
Application number
CL2016000379A
Other languages
English (en)
Inventor
Kenneth Eugene Lebioda
Jan Ove Johansson
F Allan Gordon
Fabrizio Simone Chiacchia
Christopher Ross Armstrong Halliday
Ewelina B Kulikowski
Original Assignee
Resverlogix Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Resverlogix Corp filed Critical Resverlogix Corp
Publication of CL2016000379A1 publication Critical patent/CL2016000379A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

COMPOSICION FARMACEUTICA QUE COMPRENDE ROSUVASTATINA Y 2- (- (2-HIDROXIETOXIi) -3,5- DIMETILFENIL) -5, 7-DIMETOXIQUINAZOLIN-4 (3H) -ONA: Y UNMETODO PARA TRATAR O PREVENIR UN TRASTORNO RELACIONADO CON COLESTEROL Y LIPIDOS. (378-13)
CL2016000379A 2013-08-21 2016-02-19 Composiciones y métodos terapéuticos para reducción acelerada de plagas CL2016000379A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361868386P 2013-08-21 2013-08-21

Publications (1)

Publication Number Publication Date
CL2016000379A1 true CL2016000379A1 (es) 2016-08-26

Family

ID=52484226

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016000379A CL2016000379A1 (es) 2013-08-21 2016-02-19 Composiciones y métodos terapéuticos para reducción acelerada de plagas

Country Status (14)

Country Link
US (1) US20160206617A1 (es)
EP (1) EP3035934A4 (es)
JP (1) JP2016528275A (es)
KR (1) KR20160043117A (es)
CN (1) CN105473144A (es)
AU (1) AU2014310369A1 (es)
BR (1) BR112016003584A8 (es)
CA (1) CA2921985A1 (es)
CL (1) CL2016000379A1 (es)
EA (1) EA201690284A1 (es)
HK (1) HK1219434A1 (es)
IL (1) IL244166A0 (es)
MX (1) MX2016002302A (es)
WO (1) WO2015025226A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2118074T3 (en) 2007-02-01 2014-03-10 Resverlogix Corp Compounds for the prevention and treatment of cardiovascular diseases
CN105859639A (zh) 2009-03-18 2016-08-17 雷斯韦洛吉克斯公司 新的抗炎剂
CN107252429B (zh) 2009-04-22 2023-06-16 雷斯韦洛吉克斯公司 新抗炎剂
JP5992049B2 (ja) 2011-11-01 2016-09-14 レスバーロジックス コーポレイション 置換されたキナゾリノンのための経口速放性製剤
WO2014080291A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Biaryl derivatives as bromodomain inhibitors
WO2014080290A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Cyclic amines as bromodomain inhibitors
CN105473145A (zh) * 2013-08-21 2016-04-06 雷斯韦洛吉克斯公司 用于加速斑块消退的组合物和治疗方法
CN114984016A (zh) 2015-03-13 2022-09-02 雷斯韦洛吉克斯公司 用于治疗补体相关疾病之组合物及治疗方法
JP7502811B2 (ja) * 2019-11-05 2024-06-19 レスバーロジックス コーポレイション Ｂｅｔブロモドメイン阻害物質およびナトリウム依存性グルコース輸送体２阻害物質の組み合わせで主要な心血管有害事象（ｍａｃｅ）を処置および／または予防する方法
CN115003306A (zh) * 2020-01-08 2022-09-02 雷斯韦洛吉克斯公司 用bet溴结构域抑制剂和二肽基肽酶4抑制剂的组合治疗和/或预防主要不良心血管事件(mace)的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ556545A (en) * 2002-03-22 2009-03-31 Novartis Ag Combination comprising a beta-hydroxy-beta-methylglutaryl-co-enzyme-A reductase inhibitor and a glucagon-like peptide-1 agonist
US20080085911A1 (en) * 2006-10-10 2008-04-10 Reliant Pharmaceuticals, Inc. Statin and omega-3 fatty acids for reduction of apo-b levels
DK2118074T3 (en) * 2007-02-01 2014-03-10 Resverlogix Corp Compounds for the prevention and treatment of cardiovascular diseases
WO2012112531A1 (en) * 2011-02-16 2012-08-23 Pivotal Therapeutics, Inc. Statin and omega 3 fatty acids (epa, dha and dpa) for use in cardiovascular diseases
AU2014205553A1 (en) * 2013-01-08 2015-07-09 Volant Holdings Gmbh Activation of the endogenous ileal brake hormone pathway for organ regeneration and related compositions, methods of treatment, diagnostics, and regulatory systems
CN105473145A (zh) * 2013-08-21 2016-04-06 雷斯韦洛吉克斯公司 用于加速斑块消退的组合物和治疗方法

Also Published As

Publication number Publication date
BR112016003584A8 (pt) 2018-01-30
WO2015025226A9 (en) 2015-12-03
KR20160043117A (ko) 2016-04-20
US20160206617A1 (en) 2016-07-21
HK1219434A1 (zh) 2017-04-07
EP3035934A4 (en) 2017-04-26
WO2015025226A3 (en) 2015-06-25
CN105473144A (zh) 2016-04-06
WO2015025226A2 (en) 2015-02-26
EA201690284A1 (ru) 2016-08-31
AU2014310369A2 (en) 2016-04-21
JP2016528275A (ja) 2016-09-15
CA2921985A1 (en) 2015-02-26
AU2014310369A1 (en) 2016-03-10
EP3035934A2 (en) 2016-06-29
IL244166A0 (en) 2016-04-21
MX2016002302A (es) 2016-06-15

Similar Documents

Publication Publication Date Title
CL2016000379A1 (es) Composiciones y métodos terapéuticos para reducción acelerada de plagas
SV2018005709A (es) 3-azabiciclo[3.1.0]hexanos sustituidos como inhibidores de cetohexoquinasa
MX2016002137A (es) Ciertas entidades quimicas, composiciones y metodos.
NI201600071A (es) Compuestos de inhibidor de autotaxina
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
CL2016000378A1 (es) Composiciones y métodos terapéuticos para la regresión acelerada de placa
MX378969B (es) Terapia de combinacion que incluye un inhibidor mdm2 y uno o mas agentes farmaceuticamente activos adicionales para el tratamiento de canceres.
TW201613887A (en) Antiproliferative compounds and methods of use thereof
MX2019001125A (es) Inhibidores de cinasa macrociclica.
CL2015001990A1 (es) Compuestos de pirrolopirimidina substituidos, composiciones de los mismos, y métodos de tratamiento con los mismos.
MX384490B (es) Agentes que inducen apoptosis para el tratamiento de cancer y enfermedades inmunitarias y autoinmunitarias.
CL2015002891A1 (es) Deaza-purinonas macrocíclicas para el tratamiento de infecciones virales.
MX2016002544A (es) Compuestos utiles como inmunomoduladores.
MX2015011606A (es) Metodo para tratar cancer y prevenir resistencia a farmacos contra cancer.
ECSP16008797A (es) Derivados de heterobicicloaril como inhibidores rorc2 y métodos de uso de los mismos
BR112015023074A2 (pt) agentes de ligação-met e uso dos mesmos
MX383254B (es) Combinacion que comprende un glucocorticoide y edo-s101.
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
MX394452B (es) Inhibicion de la actividad de olig2.
BR112017024163A2 (pt) compostos bicíclicos
MX371343B (es) Moduladores del receptor x hepatico (lxr).
IN2013MU03118A (es)
MX2016002930A (es) Moduladores del receptor x hepatico (lxr).
GB2543709A (en) Pharmaceutical agent
PH12020500472A1 (en) Autotaxin inhibitor compounds